Divis Laboratories
- Market Cap
- ₹2,96,807 Cr
- P/E
- 88.26
Key Fundamentals
LargecapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 22.00%
- Debt to Equity
- 0.00
- EPS (TTM)
- ₹126.68
- Book Value
- ₹677.93
- Market Cap
- ₹2,96,807 Cr
- P/E (TTM)
- 88.26
- P/B
- 16.49
- ROE
- 16.50%
- Dividend Yield
- 0.27%
- EBITDA
- ₹3,948 Cr
- 52W High
- ₹11,824.00
- 52W Low
- ₹5,647.50
- Day Range
- ₹11,025.00 – ₹11,198.00
- Volume
- 4,04,825
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| Median 7 companies | 1,884.90 | 41.44 | 1,23,980 | 5.07 | 0.57% | 16.50% | 17.80% | 28,139 | 2,855 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 53
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 24
- Poor
- Cheap vs sector & own history 24% weight
- Growth
- 67
- Strong
- Sales & profit trajectory 9% weight
- Financial Health
- 86
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 92
- Strong
- Trend strength, vol-adjusted 12% weight
- Ownership
- 48
- Average
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 39.0%
Weaknesses
2- Stock is trading at 16.5 times its book value
- The company has delivered a poor sales growth of 8.67% over past five years.
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 1 | 5 | 13 |
| Oscillators | Bullish | 0 | 5 | 4 |
| Moving Averages | Strong Bullish | 1 | 0 | 9 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 67.80
- Neutral
- MACD (12,26,9)
- 488.33
- Bullish
- SMA (50)
- 9,808.49
- Bullish
- SMA (200)
- 7,660.39
- Bullish
As of
Analyst Rating
14 of 26 analysts rate Buy, 5 Hold, 7 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +10.83% |
|---|---|
| 5Y | +8.67% |
| 3Y | +10.78% |
| 1Y | +12.82% |
| TTM | +21.56% |
Net profit
| 10Y | +8.59% |
|---|---|
| 5Y | +5.30% |
| 3Y | +12.10% |
| 1Y | +17.21% |
| TTM | +35.33% |
Operating cash flow
| 10Y | +10.19% |
|---|---|
| 5Y | +7.06% |
| 3Y | +3.63% |
| 1Y | +65.64% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −5.10 pp |
|---|---|
| 5Y | −8.55 pp |
| 3Y | +2.08 pp |
| 1Y | +0.83 pp |
| TTM | +5.73 pp |
Revenue by year
| Mar 2017 | ₹4,064 Cr |
|---|---|
| Mar 2018 | ₹3,891 Cr |
| Mar 2019 | ₹4,946 Cr |
| Mar 2020 | ₹5,394 Cr |
| Mar 2021 | ₹6,969 Cr |
| Mar 2022 | ₹8,960 Cr |
| Mar 2023 | ₹7,768 Cr |
| Mar 2024 | ₹7,845 Cr |
| Mar 2025 | ₹9,360 Cr |
| Mar 2026 | ₹10,560 Cr |
Net profit by year
| Mar 2017 | ₹1,060 Cr |
|---|---|
| Mar 2018 | ₹877 Cr |
| Mar 2019 | ₹1,353 Cr |
| Mar 2020 | ₹1,377 Cr |
| Mar 2021 | ₹1,984 Cr |
| Mar 2022 | ₹2,960 Cr |
| Mar 2023 | ₹1,823 Cr |
| Mar 2024 | ₹1,600 Cr |
| Mar 2025 | ₹2,191 Cr |
| Mar 2026 | ₹2,568 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Divis Laboratories trades at ₹11,080 as of 2026-11-16 with a market cap of ₹2,94,139 crore. The company is virtually debt-free with a debt-to-equity ratio of 0 and has delivered a TTM sales growth of 22% and TTM profit growth of 38%, though the stock commands a premium valuation at a PE of 87.46x and a price-to-book of 16.34x.
- The company is completely debt-free with a debt-to-equity ratio of 0, providing strong financial flexibility and resilience across business cycles.
- TTM profit growth stands at 38%, a sharp acceleration compared to the 5-year compounded profit growth of 6% and 3-year CAGR of 13%, indicating a meaningful earnings recovery.
- TTM revenue growth of 22% is well above the 5-year compounded sales CAGR of 9% and the 10-year CAGR of 11%, suggesting improving demand momentum.
- The stock has delivered a 1-year return CAGR of 76%, rising from a 52-week low of ₹5,647.50 to ₹11,080, reflecting strong market confidence in the business turnaround.
- 10-year average ROE of 18% and last year's ROE of 17% demonstrate consistently healthy capital efficiency for a debt-free company.
- The company maintains a healthy dividend payout ratio of 39.0%, returning a meaningful share of profits to shareholders even while reinvesting for growth.
- ROCE stands at 18.96%, which is attractive for a zero-debt business and indicates efficient deployment of total capital employed.
- Long-term compounded sales growth of 11% over 10 years and a 10-year stock CAGR of 26% reflect a durable franchise with sustained wealth creation.
- The trailing PE of 87.46x is extremely elevated, implying the market is pricing in substantial future earnings growth that may already be reflected in the stock price.
- Five-year compounded sales growth of only 9% and compounded profit growth of just 6% over the same period suggest the recent TTM acceleration may not be sustainable over longer horizons.
- Dividend yield is a mere 0.26%, offering negligible income return to shareholders at the current price of ₹11,080.
- ROE of 15.32% on a trailing basis has dipped below the 10-year average of 18%, indicating some compression in return on equity despite the debt-free balance sheet.
- The 5-year stock CAGR of 18% lags the 3-year CAGR of 48% and 1-year CAGR of 76%, suggesting much of the recent re-rating is concentrated in a short window and may be vulnerable to mean reversion.
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Limited recent news flow for Divis Laboratories. The only notable event is a sizable block trade worth ₹194.80 crore on Oct 22, which by itself is neither bullish nor bearish without knowing the counterparties or motive. With no fresh headwinds or positive catalysts in the latest cycle, the near-term outlook hinges on upcoming quarterly results and broader pharma sector sentiment.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,909 | 1,855 | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 | 3,676 |
| Expenses | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 | 1,699 | 1,681 | 1,827 | 1,714 | 1,897 | 1,825 | 2,110 |
| Operating Profit | 479 | 489 | 731 | 622 | 716 | 743 | 886 | 729 | 888 | 890 | 934 | 1,255 | 1,566 |
| OPM % | 25% | 26% | 32% | 29% | 31% | 32% | 34% | 30% | 33% | 34% | 33% | 41% | 43% |
| Other Income | 86 | 95 | 79 | 79 | 106 | 82 | 86 | 119 | 145 | 14 | 155 | 64 | 94 |
| Interest | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 8 | 6 | 6 | 6 | 13 |
| Depreciation | 95 | 95 | 95 | 97 | 99 | 99 | 107 | 112 | 113 | 118 | 120 | 133 | 142 |
| PBT | 469 | 489 | 713 | 604 | 722 | 726 | 864 | 733 | 912 | 780 | 963 | 1,180 | 1,505 |
| Tax % | 26% | 27% | 25% | 29% | 29% | 19% | 23% | 26% | 24% | 25% | 22% | 24% | 25% |
| Net Profit | 348 | 358 | 538 | 430 | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 | 1,127 |
| EPS (₹) | 13.11 | 13.49 | 20.27 | 16.20 | 19.21 | 22.19 | 24.94 | 20.53 | 25.95 | 21.96 | 28.29 | 33.98 | 42.45 |
| YoY Sales growth | 3 | 9 | 18 | 19 | 22 | 25 | 12 | 14 | 16 | 12 | 10 | 28 | 35 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,115 | 3,776 | 4,064 | 3,891 | 4,946 | 5,394 | 6,969 | 8,960 | 7,768 | 7,845 | 9,360 | 10,560 | 12,191 |
| Expenses | 1,942 | 2,354 | 2,615 | 2,622 | 3,072 | 3,568 | 4,102 | 5,075 | 5,397 | 5,635 | 6,387 | 7,118 | 7,546 |
| Operating Profit | 1,173 | 1,423 | 1,450 | 1,269 | 1,874 | 1,826 | 2,867 | 3,885 | 2,370 | 2,210 | 2,973 | 3,442 | 4,645 |
| OPM % | 38% | 38% | 36% | 33% | 38% | 34% | 41% | 43% | 31% | 28% | 32% | 33% | 38% |
| Other Income | 38 | 93 | 72 | 107 | 154 | 186 | 57 | 112 | 344 | 335 | 348 | 507 | 327 |
| Interest | 3 | 5 | 3 | 1.33 | 5 | 6.1 | 0.87 | 2 | 2 | 3 | 2 | 23 | 31 |
| Depreciation | 136 | 118 | 123 | 142 | 169 | 186 | 256 | 312 | 343 | 378 | 402 | 463 | 513 |
| Exceptional Items | — | — | — | — | — | — | — | — | — | — | — | −74 | — |
| PBT | 1,072 | 1,393 | 1,395 | 1,231 | 1,855 | 1,819 | 2,666 | 3,684 | 2,369 | 2,163 | 2,916 | 3,388 | 4,428 |
| Tax % | 21% | 19% | 24% | 29% | 27% | 24% | 26% | 20% | 23% | 26% | 25% | 24% | — |
| Net Profit | 852 | 1,126 | 1,060 | 877 | 1,353 | 1,377 | 1,984 | 2,960 | 1,823 | 1,600 | 2,191 | 2,568 | 3,363 |
| EPS (₹) | 32.07 | 42.41 | 39.95 | 33.04 | 50.96 | 51.85 | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 | 96.73 | 126.68 |
| Div. Payout % | 31% | 24% | 25% | 30% | 31% | 31% | 27% | 27% | 44% | 50% | 36% | 31% | — |
| Sales growth | 23 | 21 | 8 | −4 | 27 | 9 | 29 | 29 | −13 | 1 | 19 | 13 | 22 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 27 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 | 53 |
| Reserves | 3,469 | 4,240 | 5,304 | 5,872 | 6,904 | 7,257 | 9,242 | 11,675 | 12,714 | 13,518 | 14,916 | 16,708 | 17,944 |
| Borrowings | 27 | 42 | 36 | 63 | 106 | 39 | 5 | 4 | 3 | 3 | 4 | 7 | 6 |
| Other Liabilities | 883 | 562 | 762 | 797 | 973 | 1,183 | 1,471 | 1,628 | 1,654 | 1,886 | 1,948 | 3,251 | 3,961 |
| Total Liabilities | 4,405 | 4,898 | 6,155 | 6,785 | 8,036 | 8,531 | 10,771 | 13,360 | 14,425 | 15,460 | 16,921 | 20,019 | 21,964 |
| Fixed Assets | 1,309 | 1,439 | 1,559 | 1,996 | 2,088 | 2,782 | 3,704 | 4,325 | 4,723 | 4,739 | 5,442 | 6,528 | 7,473 |
| CWIP | 218 | 264 | 444 | 120 | 492 | 920 | 711 | 470 | 212 | 778 | 1,022 | 2,113 | 1,638 |
| Investments | 733 | 803 | 1,631 | 1,889 | 1,946 | 971 | 0 | 72 | 77 | 82 | 65 | 69 | 71 |
| Other Assets | 2,145 | 2,392 | 2,521 | 2,780 | 3,511 | 3,858 | 6,356 | 8,493 | 9,413 | 9,861 | 10,392 | 11,309 | 12,782 |
| Total Assets | 4,405 | 4,898 | 6,155 | 6,785 | 8,036 | 8,531 | 10,771 | 13,360 | 14,425 | 15,460 | 16,921 | 20,019 | 21,964 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 826 | 1,038 | 1,150 | 776 | 954 | 1,216 | 1,947 | 1,912 | 2,460 | 1,261 | 1,653 | 2,738 |
| Investing | −521 | −406 | −1,140 | −478 | −685 | −83 | 75 | −2,195 | −2,708 | −269 | −804 | −2,219 |
| Financing | −303 | −631 | 2 | −314 | −246 | −1,091 | −35 | −532 | −797 | −799 | −799 | −804 |
| Net Cash Flow | 3 | 0 | 13 | −17 | 23 | 41 | 1,987 | −816 | −1,045 | 193 | 50 | −285 |
| Free Cash Flow | 519 | 642 | 774 | 502 | 221 | 33 | 1,037 | 1,199 | 1,987 | 258 | 215 | 221 |
| CFO/EBITDA | 88 | 91 | 100 | 82 | 77 | 91 | 90 | 66 | 124 | 74 | 83 | 105 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 87 | 85 | 81 | 95 | 86 | 96 | 88 | 99 | 84 | 100 | 106 | 103 |
| Inventory Days | 350 | 293 | 307 | 314 | 347 | 316 | 329 | 341 | 352 | 364 | 311 | 346 |
| Days Payable | 68 | 56 | 104 | 96 | 96 | 100 | 117 | 96 | 89 | 94 | 88 | 106 |
| Cash Conversion Cycle | 368 | 322 | 284 | 313 | 336 | 312 | 300 | 344 | 347 | 370 | 330 | 343 |
| Working Capital Days | 140 | 158 | 147 | 176 | 169 | 180 | 152 | 177 | 188 | 206 | 192 | 195 |
| ROCE % | 33% | 36% | 29% | 22% | 29% | 25% | 32% | 35% | 19% | 16% | 20% | 22% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Divis Laboratories insights
72 extracted metrics across FY06–FY27.
Documents
- Q2 FY27 concall · Nov 2026Transcript Recording
- Q1 FY27 concall · Aug 2026Transcript Recording
- Q4 FY26 concall · May 2026Transcript
- Q3 FY26 concall · Feb 2026Transcript Recording
- Q2 FY26 concall · Nov 2025Transcript Recording
- 25 May 2026
- 7 Sep 2026
- 26 Aug 2025
- 13 Sep 2024
- 12 Sep 2023
- 4 Oct 2022
- General announcements 2 Nov 2026
Frequently Asked Questions about Divis Laboratories
What does Divis Laboratories Ltd do?
Where is Divis Laboratories Ltd (DIVISLAB) listed?
Which sector does Divis Laboratories Ltd belong to?
What is the market capitalisation of Divis Laboratories Ltd?
What is the PE ratio of Divis Laboratories Ltd?
What is the 52-week high and low of Divis Laboratories Ltd?
Does Divis Laboratories Ltd pay dividends?
What is the Return on Equity (ROE) of Divis Laboratories Ltd?
Company Information
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/DIVISLAB.md for Divis Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.